Our Pipeline

BioShin is a development and commercialization company focused on advancing therapies for which there are currently no adequate treatment options.

It was established in China with a three-platform portfolio of four late-stage clinical assets to treat neuro-immune diseases, in-licensed from strategic partner and U.S. pharmaceutical company Biohaven: calcitonin gene-related peptide (CGRP) receptor antagonism (including the potential blockbuster drug rimegepant), glutamate modulation, and myeloperoxidase (MPO) inhibition.